Scholar Rock Sets $11,659 Per Vial Price for First SMA Muscle-Targeting Drug
SRRK has more than doubled off its 52-week low of $27.07.
Summary
Scholar Rock priced Isembyld (apitegromab) at $11,659 per single-use vial, with a typical annual net cost of $310,000. This is the first commercial pricing for the newly approved SMA therapy, following FDA approval on September 11. The price point is material for revenue modeling and payer negotiations. The company's cash runway extends into 2027, and this launch marks its transition to a commercial-stage biotech. Watch for initial prescription trends and payer coverage decisions in the coming quarters.
At the time of this announcement, SRRK was trading at $58.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $27.07 to $61.76. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.